Comprehensive In Vivo CAR-T Development Solutions

The Rationale of CAR-T Development

CAR-T cell therapy has made great achievements in the past decade, while conventional CAR-T cell therapy also has some obstacles to overcome, such as the CRS and ICANS toxicity, and the expensive and complex manufacturing process. The in-vivo CAR-T cell engineering by nanoparticles carrying CAR genes and gene-editing tools has shown potential breakthroughs in overcoming the above obstacles of traditional CAR-T cell therapies. Therefore, there is more urgent to develop safe and simple in-vivo CAR-T cell engineering solutions.

Fig.1 Comparison of generating CAR-T in-vitro and CAR-T in-vivo. (Xin, et al., 2022)

Our In Vivo CAR-T Cell Engineering Services

To overcome the limitations of current CAR-T therapy, Creative Biolabs has developed one-stop in vivo CAR-T cell engineering services to support global customers. Our in vivo CAR-T cell engineering carries engineered CAR genes through delivery systems (such as non-viral or viral systems) characterized by multiple functions to overcome the obstacles of current CAR-T, such as CRS & ICANS toxicities, immunosuppressive microenvironments, and complex manufacturing processes.

Highlights of Our Services

Our in vivo CAR-T cell engineering services have the following characteristics.

What We Can Offer

• Optimized Functional Testing

We run comprehensive in vitro tests (expression, viability, activation) and in vivo evaluations (biodistribution, persistence, safety) to validate performance.

• Integrated Analytical Support

Expert data interpretation, detailed reporting, and guidance to help you make decisions and refine your strategy for subsequent development phases.

• Modular Service Options

Whether you need just the CAR design, delivery development, or full in vivo programming + validation, our services are modular and customizable.

• Experienced Scientific Team

Our team has deep expertise in both CAR engineering and in vivo delivery systems, with a track record across multiple platforms and cell types.

Discover How We Can Help - Request a Consultation

Process

We follow a structured and comprehensive workflow to guide your in vivo CAR‑T project from initial concept to functional validation, ensuring clarity, efficiency, and reliable results at every step.

Published Data

Paper title: Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering

Summary: Researchers established a lentiviral vector-based platform for in vivo CAR-T cell engineering: UB-VV100. Which encodes a 2^nd CD19-targeted CAR displayed an anti-CD3 scFv on the surface with a rapamycin-activated cytokine receptor (RACR) system additionally designed for the treatment of B-cell malignancies. The study found that this strategy produced functional CAR-T cells with favorable biodistribution characteristics in vivo.

Technology: lentiviral-based CD19 CAR vector for in vivo CAR T-cell engineering;

Tumor Type: B-cell malignancy;

Advantages

• Flexible, Scalable Platform

Whether your project is preclinical research or translational development, our modular services can adapt to your needs.

• Robust Validation

We support in-depth functional and safety testing in physiologically relevant models, giving you confidence in the performance of your in vivo engineered CAR-T cells.

• Collaborative Approach

We work closely with clients, providing strategic input, data-driven insights, and continuous communication throughout the project lifecycle.

Frequently Asked Questions

If you are interested in our CellRapeutics™ in vivo CAR-T cell engineering services, please feel free to contact us to learn more.

Why Choose Us

With extensive experience in in vivo CAR‑T engineering, we provide modular, flexible solutions covering CAR design, delivery optimization, and functional validation. Our platform ensures efficiency, safety, and robust performance evaluation, supporting both preclinical and translational research. Partner with us to accelerate your project. Contact our team today to discuss your in vivo CAR‑T needs and explore tailored solutions.

References

1. Michels, K.R.; et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer. 2023,11(3):e006292.
2. Xin, T.; et al. In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy. Front Oncol. 2022,12:809754.